Investors + Media

Company Overview

Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company's proprietary zinc finger nuclease (ZFN) in vivo genome editing approach is being evaluated in Phase 1/2 clinical trials to treat hemophilia B and lysosomal storage disorders MPS I and MPS II. In 2017 Sangamo is also conducting a Phase 1/2 clinical trial to evaluate its AAV cDNA human Factor 8 gene therapy approach, SB-525, to treat hemophilia A. Sangamo has a strategic collaboration with Bioverativ, Inc. for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington's disease. In addition, Sangamo has Phase 1/2 and Phase 2 clinical programs in HIV/AIDS (SB-728). It has established strategic partnerships with companies in non-therapeutic applications of its technology, including Sigma-Aldrich Corporation and Dow AgroSciences.

View Leadership

Sign Up For E-Mail Alerts

Sign Up

Stock SnapshotView Detailed Stock Info

Sangamo Therapeutics, Inc.

Market/Symbol NASDAQ: SGMO
Market Cap
Day Range
52 WK Range

Quarterly Results

Q2 2017

Quarterly Results

Quarter Ended Jun 30, 2017
Annual Report

Latest 10-K + Proxy

IR Contact Information

Investor Relations

McDavid Stilwell
Corporate Communications
T: 510-970-6000 x219
F: 510-236-8951

Transfer Agent

Computershare, Inc.
250 Royall Street
Canton, MA 02021
T: 781-575-3951
F: 781-575-2152